Abstract: The impact of body mass index (BMI) on postoperative nausea and vomiting (PONV) is controversial, and few studies have focused on their relationship. We investigated the effects of BMI on PONV, taking into account other PONV risk factors. We analyzed adults over the age of 18 years who received general anesthesia between 2015 and 2019, using propensity score matching. Before propensity score matching, odds ratios (ORs) for PONV were lower for overweight (OR, 0.91; 95% confidence interval (CI), 0.87–0.96; \( p < 0.0001 \)) or obese patients (OR, 0.77; 95% CI, 0.71–0.84; \( p < 0.0001 \)) than for normal-BMI patients. After matching, the ORs for PONV of overweight (OR, 0.89; 95% CI, 0.80–0.98; \( p = 0.016 \)) and obese patients (OR, 0.71; 95% CI, 0.63–0.79; \( p < 0.0001 \)) were low. However, the ORs of underweight patients did not differ from those of normal-BMI patients, irrespective of matching. Therefore, the incidence of PONV may be lower among adults with a higher-than-normal BMI.

Keywords: body mass index; obesity; overweight; postoperative nausea and vomiting

1. Introduction

Postoperative nausea and vomiting (PONV) are common complications of anesthesia [1] that occur in 30% of hospitalized patients; moreover, their incidences are significantly greater in high-risk patients [2]. In previous studies, vomiting was the most undesirable outcome of patients after surgery, and nausea was the fourth most undesirable outcome [3]. PONV is usually non-fatal [4] but, in rare cases, can cause serious pathological conditions such as dehydration, electrolyte imbalance, suture tension and dislocation, venous hypertension and bleeding, aspiration of gastric contents, esophageal rupture, and life-threatening airway damage [5–7].

Several studies have identified factors that alleviate or exacerbate PONV [2,5,6,8–10]. However, whether obesity is a risk factor for PONV is controversial. A relatively high body mass index (BMI) may promote PONV [8,11], but the opposite effect has also been reported [12–14]. Others have found that BMI is not a risk factor for PONV [15,16].

Many previous PONV studies were retrospective observational studies [12,13,17–19]. As observational studies conduct research in specific groups without random assignment, they are slightly more realistic representations of the clinical situation, and statistical controls can be applied for specific confounding variables. However, observational studies cannot avoid selection bias. It is fundamentally impossible to deduce the cause of a phenomenon in studies that are not based on random assignment. Matching
methods are generally used in observational studies to reduce selection bias [20]. Propensity score matching (PSM) is used not only in observational studies but also in retrospective research where it is difficult to apply random assignment [21].

We investigated the effects of BMI on PONV, taking into account other risk factors for PONV. The validity of observational studies on the effects of BMI can be reduced by selection bias and confounders, so we performed propensity score matching.

2. Patients and Methods

2.1. Patients

The data were obtained from the Clinical Data Warehouse of Hallym University Medical Center, and the study was approved by the Clinical Research Ethics Committee of Chuncheon Sacred Heart Hospital, Hallym University (Institutional Review Board no. 2020-03-011). The patients were at least 18 years of age and had undergone surgery under general anesthesia at Hallym University Medical Center between January 2015 and December 2019. The exclusion criteria were as follows: patients who received repeat surgery within 24 h after anesthesia, patients who were unconscious after surgery, patients who underwent ventilator therapy after anesthesia, patients with nausea or vomiting before anesthesia, and patients with data missing from their medical records.

2.2. BMI, PONV, and Covariates

BMI is defined as weight (in kilograms) divided by the square of the height (in meters). In this study, patients with BMI <18.5, 18.5–25, 25.1–30, or >30 were considered underweight, normal weight, overweight, or obese, respectively. PONV was defined as the occurrence of nausea or vomiting within 24 h after anesthesia as recorded in medical records. This study did not consider nausea or vomiting events as separate outcomes because they have identical risk factors and predictors [17,22–27], postoperative nausea may be considered a symptom for potential vomiting [28], and the accompanying occurrence of nausea and vomiting is more than the individual occurrences of nausea and vomiting [6]. Covariates included age; sex; height; operation duration; American Society of Anesthesiologists physical status; use of N\textsubscript{2}O during anesthesia maintenance; patient-controlled analgesia after surgery; history of diabetes, gastroesophageal reflux disease, or smoking; use of antiemetics, opioids, proton-pump inhibitors, or antibiotics; use of a Levin tube during and after surgery; laparoscopic surgery; and transfusion during surgery.

2.3. Statistics

Continuous data are presented as means and standard deviations and categorical data as frequencies and percentages. For continuous data, t-tests were performed to compare between patients with and without PONV. Categorical data were analyzed by chi-squared test. First, the odds ratio (OR), with 95% confidence interval (CI), for occurrence of PONV within 24 h after surgery was calculated for each variable by logistic regression. The odds ratio (OR) is a measure of the association between an exposure and an outcome [29], and the OR in this study represented the likelihood of PONV given a particular exposure (underweight, overweight, obese) compared to the likelihood of PONV in the absence of this exposure. Next, the adjusted OR for PONV according to BMI category was determined. Finally, the ORs adjusted for all variables and for those variables selected by backward elimination were calculated.

As patients cannot be randomized based on BMI category, confounding and selection bias were accounted for by developing propensity scores for the BMI categories. The rationale for, and method of, using propensity scores for the proposed causal exposure variables have been described elsewhere [30,31]. We performed three rounds of propensity score matching: normal BMI matched with underweight, normal BMI matched with overweight, and normal BMI matched with obese patients. Anaconda (Python version 3.7, https://www.anaconda.com; Anaconda Inc., Austin, TX, USA)
and pymatch (version 0.3.4; https://github.com/benmiroglio/pymatch) were used for propensity score matching. The propensity scores were 0.26–0.87, 0.30–0.68, and 0.21–0.83 for matched normal and underweight, normal and overweight, and normal and obese patients, respectively. All matched records had scores within 0.0001 of each other, and all matching ratios were 1:1. We matched 4063 underweight patients with 4063 normal-BMI patients, 9872 overweight patients with 9872 normal-BMI patients, and 7678 obese patients with 7678 normal-BMI patients.

The ORs for PONV in underweight, overweight, and obese patients were compared with that of normal-BMI patients. In each analysis, covariates and propensity scores were used to calculate the adjusted OR. All \( p \)-values were two-sided, and a \( p \)-value < 0.05 was considered indicative of statistical significance. SPSS software (version 24.0; IBM Corp., Armonk, NY, USA) was used for the statistical analyses. The dataset used is provided in Supplementary File S1.

3. Results

Patient Characteristics

Between January 2015 and December 2019, a total of 113,881 patients underwent general anesthesia in Hallym University Medical Center. After excluding 10,320 patients, 103,561 were included in the study (Figure 1). PONV occurred within 24 h after surgery in 10,404 of these patients; their baseline characteristics are listed in Table 1. The adjusted and unadjusted ORs for developing PONV are listed in Table 2. The ORs for PONV were higher in overweight (unadjusted OR, 0.85 (95% CI, 0.81–0.89); fully adjusted OR, 0.91 (95% CI, 0.87–0.96)) and obese (unadjusted OR, 0.79 (95% CI, 0.73–0.86); fully adjusted OR, 0.77 (95% CI, 0.71–0.84)) patients compared with normal-BMI patients.

| Table 1. Baseline characteristics of the subjects. |
|-----------------------------------------------|
|                  | PONV (+) \( n = 10,404 \) | PONV (−) \( n = 93,157 \) | \( p \) |
|------------------|----------------------------|-----------------------------|--------|
| Age (years, mean ± SD) | 50.7 ± 16.5 | 50.6 ± 17.1 | 0.538  |
| Female (n, (%)) | 7561 (72.7) | 45,470 (48.8) | <0.0001 |
| Height (cm, mean ± SD) | 160.5 ± 9.1 | 163.6 ± 9.4 | <0.0001 |
| BMI (n, (%)) | | | |
| <19.9 | 469 (4.5) | 3595 (3.9) | <0.0001 |
| 20–24.9 | 6250 (60.1) | 52,573 (56.4) | <0.0001 |
| ≥25–29.9 | 3023 (29.1) | 29,972 (32.2) | <0.0001 |
| ≤30 | 662 (6.4) | 7017 (7.5) | <0.0001 |
| Operation time (h, mean ± SD) | 2.5 ± 1.5 | 2.1 ± 1.5 | <0.0001 |
| ASA PS ≥ 3 (n, (%)) | 1540 (14.8) | 14,162 (15.2) | 0.280  |
| N2O (n, (%)) | 1474 (14.2) | 16,357 (17.6) | <0.0001 |
| PCA (n, (%)) | 7261 (69.8) | 40,869 (43.9) | <0.0001 |
| DM (n, (%)) | 1184 (11.4) | 12,274 (13.2) | <0.0001 |
| Smoking (n, (%)) | 899 (8.6) | 18,118 (19.4) | <0.0001 |
| Opioids (n, (%)) | 9465 (91.0) | 81,974 (88.0) | <0.0001 |
| Antiemetics (n, (%)) | 7563 (72.7) | 47,421 (50.9) | <0.0001 |
| Neostigmine (n, (%)) | 3292 (31.6) | 23,380 (25.1) | <0.0001 |
| PPI (n, (%)) | 709 (6.8) | 6599 (7.1) | 0.309  |
| GERD (n, (%)) | 171 (1.6) | 1653 (1.8) | 0.336  |
| Antibiotics (n, (%)) | 9150 (87.9) | 81,224 (87.2) | 0.028  |
| Levin tube (n, (%)) | 227 (2.2) | 1743 (1.9) | 0.028  |
| Laparoscopic surgery (n, (%)) | 3189 (30.7) | 21,657 (23.2) | <0.0001 |
| Transfusion (n, (%)) | 455 (4.4) | 3425 (3.7) | <0.0001 |

PONV, postoperative nausea and vomiting; SD, standard deviation; ASAPS, American Society of Anesthesiologists physical status; PCA, patient-controlled analgesia; DM, diabetes; GERD, gastroesophageal reflux disease; PPI, proton-pump inhibitor; BMI, body mass index.
113,881 patients over 18 years of age underwent general anesthesia.

10,320 patients were excluded.
881 patients were reoperated within 24 hours
3,905 patients were unconscious.
3,909 patients underwent ventilator therapy after surgery.
1,102 patients had nausea or vomiting before surgery.
523 patients had missing medical records.

103,561 patients were included in the study.

Propensity score matching

4,064 underweight patients & 4,064 normal BMI patient

9,872 overweight patients & 9,872 normal BMI patient

7,679 obese patients & 7,679 normal BMI patient

Figure 1. Flow chart.
Table 2. Unadjusted and fully adjusted odds ratios (ORs) of each variable for postoperative nausea and vomiting.

| Variable               | Unadjusted OR (95% CI) | p       | Fully Adjusted OR (95% CI) | p       |
|------------------------|------------------------|---------|-----------------------------|---------|
| Age                    | 1.00 (1.00–1.00)       | 0.549   | 0.99 (0.99–1.00)            | <0.0001 |
| Female                 | 2.79 (2.67–2.92)       | <0.0001 | 2.21 (2.06–2.36)            | <0.0001 |
| Height                 | 0.97 (0.96–0.97)       | <0.0001 | 1.00 (0.99–1.00)            | 0.039   |
| Operation time         | 1.14 (1.12–1.15)       | <0.0001 | 1.06 (1.04–1.07)            | <0.0001 |
| ASA PS 3–5 vs. 1–2     | 0.97 (0.92–1.03)       | 0.280   | 0.88 (0.83–0.95)            | <0.0001 |
| N2O                    | 0.78 (0.73–0.82)       | <0.0001 | 0.81 (0.76–0.87)            | <0.0001 |
| PCA                    | 2.96 (2.83–3.09)       | <0.0001 | 2.21 (2.05–2.39)            | <0.0001 |
| Diabetes               | 0.85 (0.79–0.90)       | <0.0001 | 0.93 (0.87–1.00)            | 0.049   |
| Smoking                | 0.39 (0.37–0.42)       | <0.0001 | 0.61 (0.56–0.65)            | <0.0001 |
| Opioids                | 1.38 (1.28–1.48)       | <0.0001 | 1.10 (1.01–1.20)            | 0.025   |
| Antiemetics            | 2.57 (2.46–2.69)       | <0.0001 | 1.47 (1.36–1.60)            | <0.0001 |
| Neostigmine            | 1.38 (1.32–1.44)       | <0.0001 | 1.40 (1.33–1.47)            | <0.0001 |
| Proton-pump inhibitor  | 0.96 (0.89–1.04)       | 0.310   | 0.84 (0.77–0.92)            | <0.0001 |
| GERD                   | 0.93 (0.79–1.08)       | 0.336   | 1.14 (0.97–1.34)            | 0.115   |
| Antibiotics            | 1.07 (1.01–1.14)       | 0.028   | 0.88 (0.83–0.95)            | 0.001   |
| Levin tube             | 1.17 (1.02–1.35)       | 0.028   | 0.80 (0.70–0.93)            | 0.003   |
| Laparoscopic surgery   | 1.46 (1.40–1.53)       | <0.0001 | 1.17 (1.12–1.23)            | <0.0001 |
| Transfusion            | 1.20 (1.08–1.32)       | <0.0001 | 0.85 (0.77–0.94)            | 0.002   |
| Underweight vs. normal BMI | 1.10 (0.99–1.21)   | 0.068   | 1.05 (0.94–1.16)            | 0.406   |
| Overweight vs. normal BMI | 0.85 (0.81–0.89)   | <0.0001 | 0.91 (0.87–0.96)            | <0.0001 |
| Obese vs. normal BMI   | 0.79 (0.73–0.86)       | <0.0001 | 0.77 (0.71–0.84)            | <0.0001 |

PONV, postoperative nausea and vomiting; OR, odds ratio; CI, confidence interval; ASAPS, American Society of Anesthesiologists physical status; PCA, patient-controlled analgesia; GERD, gastroesophageal reflux disease; PPI, proton-pump inhibitor; BMI, body mass index.

Between normal-BMI and underweight patients, there were significant differences in 10 variables before matching and no significant difference in any variable after matching (Table 3). Between normal-BMI and overweight patients, there were significant differences in 14 variables before matching and a significant difference in 1 variable (diabetes, \( p = 0.008 \)) after matching (Table 4). Between normal-BMI and obese patients, there were significant differences in nine variables before matching and no significant difference in any variable after matching (Table 5).

Table 3. Baseline characteristics of normal-BMI and underweight subjects, and comparison before and after propensity score matching.

| Variable         | Before PSM | After PSM |
|------------------|------------|-----------|
| Normal \( (n = 58,823) \) | UW \( (n = 4064) \) | D | p | Normal \( (n = 4064) \) | UW \( (n = 4064) \) | D | p |
| Age              | 50.3 (17.4) | 49.8 (21.9) | 0.02 | 0.147 | 50.1 (18.4) | 49.8 (21.9) | 0.01 | 0.598 |
| Height           | 163.1 (9.0) | 162.5 (8.8) | 0.07 | <0.0001 | 162.3 (8.8) | 162.5 (8.8) | 0.01 | 0.535 |
| Female           | 31,555 (53.6) | 2498 (61.5) | 0.18 | <0.0001 | 2501 (61.5) | 2498 (61.5) | 0.03 | 0.945 |
| Operation time   | 2.1 (1.5) | 2.1 (1.4) | 0.01 | 0.630 | 2.1(1.4) | 2.1 (1.4) | 0.04 | 0.108 |
| ASA PS 3 vs. 1–2 | 8735 (14.8) | 953 (23.4) | 0.31 | <0.0001 | 983 (24.2) | 953 (23.4) | 0.02 | 0.435 |
| N2O              | 10,127 (17.2) | 699 (17.2) | <0.01 | 0.797 | 749 (18.4) | 699 (17.2) | 0.05 | 0.147 |
| PCA              | 27,337 (46.5) | 2002 (49.3) | 0.06 | 0.001 | 1942 (48.2) | 2002 (49.3) | 0.02 | 0.340 |
| Diabetes         | 6567 (11.2) | 417 (10.3) | 0.05 | 0.076 | 423 (10.4) | 417 (10.3) | 0.01 | 0.827 |
| Smoking          | 10,500 (17.9) | 781 (19.2) | 0.05 | 0.028 | 796 (19.6) | 781 (19.2) | 0.03 | 0.293 |
| Opioids          | 51,867 (88.2) | 3521 (86.6) | 0.08 | 0.003 | 3480 (85.6) | 3521 (86.6) | 0.05 | 0.188 |
| Antibiotics      | 31,178 (53.0) | 2288 (56.3) | 0.07 | <0.0001 | 2272 (55.9) | 2288 (56.3) | 0.01 | 0.721 |
| Neostigmine      | 15,374 (26.1) | 1059 (26.1) | <0.01 | 0.913 | 1023 (25.2) | 1059 (26.1) | 0.03 | 0.360 |
| PPI              | 4268 (7.3) | 406 (10.0) | 0.19 | <0.0001 | 442 (10.9) | 406 (10.0) | 0.05 | 0.191 |
| GERD             | 975 (1.7) | 63 (1.6) | 0.04 | 0.604 | 65 (1.6) | 63 (1.6) | 0.02 | 0.859 |
| Antibiotics      | 51,372 (87.3) | 3533 (86.9) | 0.02 | 0.460 | 3527 (86.6) | 3533 (86.9) | 0.01 | 0.844 |
| Levin tube       | 1184 (2.0) | 112 (2.8) | 0.18 | 0.001 | 99 (2.4) | 112 (2.8) | 0.07 | 0.365 |
Table 3. Cont.

| Operation | Before PSM | After PSM |
|-----------|------------|-----------|
| Laparoscopic surgery | 14,692 (25.0) | 990 (24.4) |
| Transfusion | 2380 (4.0) | 327 (8.0) |

BMI, body mass index; PSM, propensity score matching; UW, underweight; D, standard mean difference; ASA PS, American Society of Anesthesiologists physical status; PCA, patient-controlled analgesia; PPI, proton-pump inhibitor; GERD, gastroesophageal reflux disease. Type of Surgery other than laparoscopic surgery before propensity score matching: Normal (brain surgery, 479; eye surgery, 1372; pharynx and tonsil surgery, 1361; ear surgery, 1030) vs. UW (brain surgery, 48; eye surgery, 96; pharynx and tonsil surgery, 76; ear surgery, 44). Type of Surgery other than laparoscopic surgery after propensity score matching: Normal (brain surgery, 42; eye surgery, 78; pharynx and tonsil surgery, 108; ear surgery, 50) vs. UW (brain surgery, 48; eye surgery, 96; pharynx and tonsil surgery, 76; ear surgery, 44).

Table 4. Baseline characteristics of normal-BMI and overweight subjects, and comparison before and after propensity score matching.

| | Before PSM | After PSM |
|-----------|------------|-----------|
| Age | 50.3 (17.4) | 52.1 (15.7) |
| Height | 163.1 (9.0) | 163.6 (9.8) |
| Female | 31,555 (53.6) | 14,862 (45.0) |
| Operation time | 2.1 (1.5) | 2.2 (1.5) |
| ASA PS ≥ 3 | 8735 (14.8) | 487 (14.7) |
| N₂O | 10,127 (17.2) | 5739 (17.4) |
| PCA | 27,337 (46.5) | 15,281 (46.3) |
| Diabetes | 6567 (11.2) | 5049 (15.3) |
| Smoking | 10,500 (17.9) | 6243 (18.9) |
| Opioids | 51,867 (88.2) | 29,277 (88.7) |
| Antiemetics | 31,178 (53.0) | 17,474 (53.0) |
| Neostigmine | 15,374 (26.1) | 889 (9.0) |
| PPI | 4268 (7.3) | 667 (6.8) |
| GERD | 975 (1.7) | 165 (1.9) |
| Antibiotics | 51,372 (87.3) | 867 (87.6) |
| Levin tube | 1184 (2.0) | 175 (1.8) |
| Laparoscopic surgery | 14,692 (25.0) | 946 (22.6) |
| Transfusion | 2380 (4.0) | 915 (2.8) |

BMI, body mass index; PSM, propensity score matching; OW, overweight; D, standard mean difference; ASA PS, American Society of Anesthesiologists physical status; PCA, patient-controlled analgesia; GERD, gastroesophageal reflux disease. Type of Surgery other than laparoscopic surgery before propensity score matching: Normal (brain surgery, 479; eye surgery, 1372; pharynx and tonsil surgery, 1361; ear surgery, 1030) vs. OW (brain surgery, 258; eye surgery, 830; pharynx and tonsil surgery, 817; ear surgery, 657). Type of Surgery other than laparoscopic surgery after propensity score matching: Normal (brain surgery, 70; eye surgery, 237; pharynx and tonsil surgery, 225; ear surgery, 159) vs. OW (brain surgery, 75; eye surgery, 235; pharynx and tonsil surgery, 292; ear surgery, 196).

Table 5. Baseline characteristics of normal-BMI and obese subjects, and comparison before and after propensity score matching.

| | Before PSM | After PSM |
|-----------|------------|-----------|
| Age | 50.3 (17.4) | 46.3 (16.1) |
| Height | 163.1 (9.0) | 163.7 (10.4) |
| Female | 31,555 (53.6) | 4119 (53.6) |
| Operation time | 2.1 (1.5) | 2.2 (1.5) |
| ASA PS ≥ 3 | 8735 (14.8) | 1167 (15.5) |
| N₂O | 10,127 (17.2) | 1301 (16.9) |
| PCA | 27,337 (46.5) | 3562 (46.4) |
| Diabetes | 6567 (11.2) | 1422 (18.5) |
The unadjusted and adjusted ORs for PONV did not differ between underweight, overweight, and obese patients. The unadjusted (Fig. 2) and adjusted (p = 0.046) ORs for PONV were lower in overweight patients than in normal-BMI patients. Moreover, the unadjusted (p < 0.0001) and adjusted (p < 0.0001) ORs for PONV were lower in overweight patients than in normal-BMI patients.

**Table 5. Cont.**

|                   | Before PSM |          | After PSM |          |
|-------------------|------------|----------|-----------|----------|
|                   | Normal     | Obese    |           | Normal    | Obese    |           |
|                   | (n = 58,823) | (n = 7679) | D  | p     | (n = 7679) | (n = 7679) | D  | p     |
| Smoking           | 10,500 (17.9) | 1493 (19.4) | 0.06 | 0.001 | 1485 (19.3) | 1493 (19.4) | <0.01 | 0.870 |
| Opioids           | 51,867 (88.2) | 6774 (88.2) | <0.01 | 0.919 | 6775 (85.6) | 6774 (88.2) | <0.01 | 0.980 |
| Antiemetics       | 31,178 (53.0) | 4044 (52.7) | 0.01 | 0.575 | 4110 (53.5) | 4044 (52.7) | 0.02 | 0.286 |
| Neostigmine       | 15,374 (26.1) | 1828 (23.8) | 0.07 | <0.0001 | 1784 (25.2) | 1828 (23.8) | 0.02 | 0.403 |
| PPI               | 4268 (7.3) | 419 (5.5) | 0.17 | <0.0001 | 442 (10.9) | 419 (5.5) | <0.01 | 0.943 |
| GERD              | 975 (1.7) | 131 (1.7) | 0.02 | 0.755 | 144 (1.9) | 131 (1.7) | 0.05 | 0.429 |
| Antibiotics       | 51,372 (87.3) | 6688 (87.1) | 0.01 | 0.555 | 6659 (86.7) | 6688 (87.1) | 0.02 | 0.488 |
| Levin tube        | 1184 (2.0) | 95 (1.2) | 0.27 | <0.0001 | 97 (1.3) | 95 (1.2) | 0.01 | 0.885 |
| Laparoscopic surgery | 14,692 (25.0) | 1718 (22.4) | 0.08 | <0.0001 | 1709 (22.3) | 1718 (22.4) | <0.01 | 0.862 |
| Transfusion       | 2380 (4.0) | 258 (3.4) | 0.11 | 0.004 | 253 (3.3) | 258 (3.4) | 0.01 | 0.822 |

BMI, body mass index; PSM, propensity score matching; D, standard mean difference; ASA PS, American Society of Anesthesiologists physical status; PCA, patient-controlled analgesia; GERD, gastroesophageal reflux disease. Type of Surgery other than laparoscopic surgery before propensity score matching: Normal (brain surgery, 479; eye surgery, 1372; pharynx and tonsil surgery, 1361; ear surgery, 1030) vs. Obese (brain surgery, 56; eye surgery, 170; pharynx and tonsil surgery, 283; ear surgery, 107). Type of Surgery other than laparoscopic surgery after propensity score matching: Normal (brain surgery, 82; eye surgery, 190; pharynx and tonsil surgery, 221; ear surgery, 132) vs. Obese (brain surgery, 56; eye surgery, 170; pharynx and tonsil surgery, 283; ear surgery, 107).

Figure 2 shows the ORs for development of PONV in underweight, overweight, and obese patients. The unadjusted and adjusted ORs for PONV did not differ significantly between underweight and normal-BMI patients. The unadjusted (p = 0.046) and adjusted (p = 0.015–0.016) ORs for PONV were lower in overweight patients than in normal-BMI patients. Moreover, the unadjusted (p < 0.0001) and adjusted (p < 0.0001) ORs for PONV were lower in overweight patients than in normal-BMI patients.

Figure 2. ORs for development of PONV in underweight, overweight, and obese patients. UA, unadjusted; FA, fully adjusted; FS, all covariates + propensity score adjusted; BE, backward elimination; CI, confidence interval; OR, odds ratio. Covariates for overweight BE: age, female, operation duration, American Society of Anesthesiologists physical status, use of N2O, patient-controlled analgesia, smoking, use of antiemetics, neostigmine, proton-pump inhibitors, or antibiotics, laparoscopic surgery, and transfusion. Covariates for obese BE: age, female, operation duration, use of N2O, patient-controlled analgesia, smoking, use of antiemetics, neostigmine, or proton-pump inhibitors, gastroesophageal reflux disease, and Levin tube.
4. Discussion

We estimated the effects of being underweight, overweight, and obese based on BMI on the incidence of PONV among 113,881 patients who underwent general anesthesia during a five-year period. The ORs for PONV were lower for overweight and obese patients compared with normal-BMI patients. However, there was no difference in the ORs for PONV between underweight patients and normal-BMI patients. After propensity score matching, the results were essentially unchanged: overweight and obese patients exhibited lower ORs for PONV compared with normal-BMI patients.

Most anesthesiologists consider that an increase in BMI increases the incidence of PONV [11]. The reason may be explained as follows. Longer anesthesia time is associated with longer reduction time of the anesthetic in obese patients [32]. The action time of the anesthetic is increased when a hydrophilic anesthetic is administered based on total body weight [33]. Obese patients have high incidence rates of diabetes [34] and gastroesophageal reflux disease [35] as well as elevated abdominal pressure [36]. Bellville et al. reported that obese patients have a significantly higher incidence of nausea and vomiting compared with those who are thin, because they have a large fat reservoir to saturate [37]; others have confirmed this positive correlation [8,38–41]. However, the rate of recovery from anesthesia also depends on the time at which the anesthetic is administered [42]. Obesity is assumed to delay recovery, especially from prolonged anesthesia, but it is unclear how changes associated with obesity (such as fat distribution and increased mass) affect the pharmacokinetics of inhaled anesthetics during anesthesia. Obesity reportedly does not affect awakening time after anesthetic administration [43]. Obesity is associated with an increased adipose tissue mass, which accounts for 20–40% of the excess weight in obese individuals. Non-fat mass includes well-dispersed tissues, such as organ and muscle mass [44,45], in which anesthetics are absorbed and diffuse quickly. Fat adjacent to well-perfused tissues rapidly absorbs anesthetics, but transfer of anesthetics between these tissues, such as subcutaneous fat or skeletal muscle fat, increases over 3 h [43]. N₂O has a low fat/blood partition coefficient and is removed from the body rapidly [42].

Although a relatively high BMI has been reported to be associated with the development of PONV, our findings showed that an increased BMI reduced the incidence of PONV. However, the mechanism underlying this inverse association is unknown. Drug elimination is generally more rapid in obese patients than in non-obese patients [46]. The clearance of some volatile anesthetics, prednisolone, and some benzodiazepines is sometimes faster in obese patients [47]. Opioids are widely used as adjuvants for anesthesia and are risk factors for PONV [42,48]. However, opioids administered during surgery have little direct effect on PONV, irrespective of the opioid in question [49]. Most opioids are biotransformed primarily in the liver, via metabolism by the cytochrome p (CYP) system, conjugated in the liver, or both [42,50]. Obesity causes anatomical, physiological, and metabolic changes that can affect the pharmacokinetics of a drug (including its absorption, distribution, metabolism, and excretion) [51–55]. However, there is no correlation between CYP activity and BMI [50]. The pharmacokinetics of propofol, which is frequently used for anesthesia induction, are not affected by obesity [42]; moreover, propofol has antiemetic activity [56].

Kranke et al. reported that a relatively high BMI was not a risk factor for PONV [15]. In contrast, in this study, higher BMI was associated with a decreased incidence of PONV. A systematic review with meta-analysis is considered the best means of providing definitive answers to research questions. However, such analysis has flaws, such as the location and design of the studies analyzed, heterogeneity, loss of data, improper subgroup analysis, conflict with new experimental data, and publication overlap [57].

No mechanism for the reduced incidence of PONV in patients with higher-than-normal BMI has yet been reported, but histamine, a neurotransmitter that stimulates various pathways and receptors that mediate nausea and vomiting [58], may play a role. Leptin is an adipocyte-derived hormone that suppresses appetite, increases energy expenditure and activation of the histaminergic system in the hypothalamus, and controls body weight [59]. The amount of body fat is directly correlated with circulating leptin levels, and serum leptin level is elevated in obese individuals and drops
during weight loss or fasting. The amount of reduction during the fasting period is significantly reduced compared to individuals of normal weight [60]. The decrease in activity of the histamine activation system may be greater in subjects with higher-than-normal BMI during perioperative fasting. Dopamine receptors, especially D2 and D3, have been shown to play important roles in inducing nausea and vomiting. This mechanism blocks adenylate cyclase, reducing the amount of cAMP in neurons in the solitary nucleus and area postrema [58,61]. Because dopamine level and global activation of dopaminergic systems are increased by stress [62], PONV can be increase after severe stress such as surgery. However, obese patients have fewer dopamine receptors than those with normal BMI [63], so patients with obesity may have less effect of dopamine for PONV than normal-BMI or underweight patients. Anticholinergics are one of the antiemetic agents. They block muscarinic receptors in the cerebral cortex and pons, causing an antiemetic effect [61]. In reversal of muscle relaxation, anticholinergics are administered concurrently with cholinesterase inhibitors to reduce the side effects of cholinesterase inhibitors. In obese patients, more anticholinergic drugs are given to reverse muscle relaxation, which may be associated with a lower incidence of PONV in obese patients.

Studies of the effect of type of surgery on the incidence of PONV have yielded conflicting results [64]. A systemic review of PONV suggested that laparoscopic surgery is associated with increased risk of PONV [21]. In this study, we included laparoscopic surgery as a covariate for the incidence of PONV. Strabismus surgery [27,65,66], adenotonsillectomy [67], and inguinal scrotal and penile procedures [68] have been reported as risk factors for PONV. However, we did not analyze the surgeries separately because these previous studies were mostly performed in pediatric patients and thus the results cannot be directly compared to our adult cohort.

Our results support and extend previous findings in several important respects. First, we demonstrated that a relatively high BMI is associated with a reduction in the incidence of PONV, as reported by others [12–14]. Second, because we focused on BMI, we were able to account for the effect of BMI category (underweight, normal BMI, overweight, and obese) on the incidence of PONV. Most PONV studies did not focus on BMI [1,3,5,6,8,11–14]. However, this study also had several limitations. First, classification of BMI cannot be randomized. Although the use of observational studies to assess effectiveness is controversial [69], rigorous observational studies may not yield misleading or biased results [70,71]. Moreover, to prevent selection bias and confounding, we performed propensity score matching with tighter adjustments than are typically used in a general multivariate analysis [30]. Nevertheless, observational studies can only partially control the element that is actually measured, and it is difficult to control elements that cannot be measured [72]. Second, although we used BMI to classify patients as underweight, overweight, and obese, BMI does not differentiate between lean body mass and fat mass [73]. In addition, BMI does not reflect the distribution of adipose tissue, which affects the absorption and distribution of a drug [43,73]. However, BMI is a convenient rule of thumb for classifying certain categories of body mass as health problems, for example, in population-based studies [74]. Third, severe obesity also represents a major problem in anesthesia and surgery. However, this study did not analyze obese patients separately as they were too few in our data (n = 253) and propensity matching was insufficient for rigorous analysis. Further research is required to clarify the relationship between severe obesity and PONV.

5. Conclusions

Multivariate analysis with PSM showed that being overweight or obese was associated with a reduced incidence of PONV compared with that of having a normal BMI but being underweight did not. Our findings indicate that a higher-than-normal BMI reduces the risk of PONV. Further prospective population-based studies are needed to determine the mechanism underlying the association between higher-than-normal BMI and reduced risk of PONV.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/6/1612/s1, Supplementary File S1 Data used for statistical analysis.

Author Contributions: J.H.K. and M.H. contributed equally to this work as the first authors. Y.S.K. and J.J.L. contributed equally to this work as the corresponding authors. Conceptualization, Y.S.K. and J.J.L.; methodology, M.H.; provision of software, J.H.K.; validation, J.H.K. and J.J.L.; formal analysis, Y.S.K.; investigation, H.S.L. and Y.J.K.; resources, H.S.L.; data curation, Y.J.K.; writing—original draft preparation, J.H.K and M.H.; writing—reviewing, and editing, Y.S.K.; data visualization, M.H.; project supervision, M.H.; project administration, J.J.L.; funding acquisition, J.J.L. All authors have read and agreed to the submitted version of the manuscript.

Funding: This research was supported by the Bio and Medical Technology Development Program of the National Research Foundation (NRF), funded by the South Korean government (MSIT) (NRF-2017M3A9E8049714 and 2017M3A9E8033205). This research was also supported by the Hallym University Research Fund (HURF).

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Eberhart, L.H.; Hogel, J.; Seeling, W.; Staack, A.M.; Geldner, G.; Georgieff, M. Evaluation of three risk scores to predict postoperative nausea and vomiting. Acta Anaesthesiol. Scand. 2000, 44, 480–488. [CrossRef] [PubMed]
2. Gan, T.J. Postoperative nausea and vomiting—Can it be eliminated? JAMA 2002, 287, 1233–1236. [CrossRef] [PubMed]
3. Macario, A.; Weinger, M.; Carney, S.; Kim, A. Which Clinical Anesthesia Outcomes Are Important to Avoid? The Perspective of Patients. Anesth. Analg. 1999, 89, 652. [CrossRef]
4. Tramer, M.R. Treatment of postoperative nausea and vomiting. BMJ 2003, 327, 762–763. [CrossRef]
5. Pierre, S.; Whelan, R. Nausea and vomiting after surgery. Contin. Educ. Anesth. Crit. Care Pain 2013, 13, 28–32. [CrossRef]
6. Apfel, C.C.; Kranke, P.; Katz, M.H.; Goepfert, C.; Papenfuss, T.; Rauch, S.; Heineck, R.; Greim, C.A.; Roewer, N. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: A randomized controlled trial of factorial design. Br. J. Anaesth. 2002, 88, 659–668. [CrossRef]
7. Scuderi, P.E.; Conlay, L.A. Postoperative nausea and vomiting and outcome. Int. Anesthesiol. Clin. 2003, 41, 165–174. [CrossRef]
8. Watcha, M.F.; White, P.F. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992, 77, 162–184. [CrossRef]
9. World Health Organization. Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser. 1995, 854, 1–452.
10. Kwon, Y.S.; Choi, J.W.; Lee, H.S.; Kim, J.H.; Kim, Y.; Lee, J.J. Effect of a Preoperative Proton Pump Inhibitor and Gastroesophageal Reflux Disease on Postoperative Nausea and Vomiting. J. Clin. Med. 2020, 9, 825. [CrossRef]
11. Eberhart, L.; Morin, A.; Feilinger, T.; Falkner, Y.; Georgieff, M.; Seeling, W. Results of a survey of anesthetists on postoperative nausea and vomiting. Anesthesiol. Intensivmed. Notf. Schmerzther. AINS 1998, 33, 545–551. [CrossRef]
12. Apipan, B.; Rummasak, D.; Wongsirichat, N. Postoperative nausea and vomiting after general anesthesia for oral and maxillofacial surgery. J. Dent. Anesth. Pain Med. 2016, 16, 273–281. [CrossRef] [PubMed]
13. Silva, A.C.; O’Ryan, E.; Poor, D.B. Postoperative nausea and vomiting (PONV) after orthognathic surgery: A retrospective study and literature review. J. Oral Maxillofac. Surg. 2006, 64, 1385–1397. [CrossRef]
14. Nitahara, K.; Sugi, Y.; Shono, S.; Hamada, T.; Higa, K. Risk factors for nausea and vomiting following vitrectomy in adults. Eur. J. Anaesthesiol. 2007, 24, 166–170. [CrossRef]
15. Kranke, P.; Apfel, C.; Papenfuss, T.; Rauch, S.; Löhmann, U.; Rübsam, B.; Greim, C.A.; Roewer, N. An increased body mass index is no risk factor for postoperative nausea and vomiting: A systematic review and results of original data. Acta Anaesthesiol. Scand. 2001, 45, 160–166. [CrossRef]
16. Cohen, M.M.; Duncan, P.G.; DeBoer, D.P.; Tweed, W.A. The postoperative interview: Assessing risk factors for nausea and vomiting. Anesth. Analg. 1994, 78, 7–16. [CrossRef]
17. Koivuranta, M.; Laara, E.; Snaire, L.; Alahuhta, S. A survey of postoperative nausea and vomiting. Anesthesia 1997, 52, 443–449. [CrossRef] [PubMed]
18. Fabling, J.M.; Gan, T.J.; Guy, J.; Borel, C.O.; el-Moalem, H.E.; Warner, D.S. Postoperative nausea and vomiting. A retrospective analysis in patients undergoing elective craniotomy. J. Neurosurg. Anesthesiol. 1997, 9, 308–312. [CrossRef] [PubMed]

19. Junger, A.; Hartmann, B.; Benson, M.; Schindler, E.; Dietrich, G.; Jost, A.; Beye-Basse, A.; Hempelmann, G. The use of an anesthesia information management system for prediction of antiemetic rescue treatment at the postanesthesia care unit. Anesth. Analg. 2001, 92, 1203–1209. [CrossRef] [PubMed]

20. Lueellen, J.K.; Shadish, W.R.; Clark, M. Propensity scores: An introduction and experimental test. Eval. Rev. 2005, 29, 530–558. [CrossRef]

21. Day, A.G. Why the Propensity for Propensity Scores? Crit. Care Med. 2015, 43, 2024–2026. [CrossRef] [PubMed]

22. Palazzo, M.; Evans, R. Logistic regression analysis of fixed patient factors for postoperative sickness: A model for risk assessment. Br. J. Anaesth. 1993, 70, 135–140. [CrossRef]

23. Van den Bosch, J.E.; Moons, K.G.; Bonsel, G.J.; Kalkman, C.J. Does measurement of preoperative anxiety have added value for predicting postoperative nausea and vomiting? Anesth. Analg. 2005, 100, 1525–1532. [CrossRef] [PubMed]

24. Apfel, Christian, C.; Läärä, E.; Koivuranta, M.; Greim, C.-A.; Roewer, N. A Simplified Risk Score for Predicting Postoperative Nausea and Vomiting. Anesthesiology 1999, 91, 109–118. [CrossRef] [PubMed]

25. Palazzo, M.; Evans, R. Logistic regression analysis of fixed patient factors for postoperative sickness: A model for risk assessment. Br. J. Anaesth. 1993, 70, 135–140. [CrossRef]

26. Apfel, C.C.; Greim, C.A.; Haubitz, I.; Goepfert, C.; Usadel, J.; Sefrin, P.; Roewer, N. A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol. Scand. 1998, 42, 495–501. [CrossRef]

27. Eberhart, L.H.; Geldner, G.; Kranke, P.; Morin, A.M.; Schau, A.M.; Fehrer, C.; Wulf, H. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth. Analg. 2004, 99, 1630–1637. [CrossRef]

28. ApfelChristian, C.; Läärä, E.; Koivuranta, M.; Greim, C.-A.; Roewer, N. A Simplified Risk Score for Predicting Postoperative Nausea and Vomiting: Conclusions from Cross-validations between Two Centers. Anesthesiol. J. Am. Soc. Anesthesiol. 1999, 91, 693–700.

29. Eberhart, L.H.; Geldner, G.; Kranke, P.; Morin, A.M.; Schau, A.M.; Fehrer, C.; Wulf, H. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth. Analg. 2004, 99, 1630–1637. [CrossRef]

30. Han, T.J. Risk Factors for Postoperative Nausea and Vomiting. Anesth. Analg. 2006, 102, 1884–1898. [CrossRef] [PubMed]

31. Szumilas, M. Explaining odds ratios. J. Can. Acad. Child Adolesc. Psychiatry 2010, 19, 227–229.

32. Joffe, M.M.; Rosenbaum, P.R. Invited commentary: Propensity scores. Am. J. Epidemiol. 1999, 150, 327–333. [CrossRef]

33. Broshart, M.A.; Schneweiss, S.; Rothman, K.J.; Glynn, R.J.; Avorn, J.; Stürmer, T. Variable selection for propensity score models. Am. J. Epidemiol. 2006, 163, 1149–1156. [CrossRef] [PubMed]

34. Weber, J.; Schmidt, J.; Wirth, S.; Schumann, S.; Philip, J.H.; Eberhart, L.H.J. Context-sensitive decrement times for inhaled anesthetics in obese patients explored with GasMan(R). J. Clin. Monit. Comput. 2020, 1–12. [CrossRef] [PubMed]

35. Lee, H. Anesthetic management of the bariatric surgery. J. Korean Med. Assoc. /IiehanlliisaHyophoe Chi 2012, 55, 10. [CrossRef]

36. Al-Goblan, A.S.; Al-Alfi, M.A.; Khan, M.Z. Mechanism linking diabetes mellitus and obesity. Diabetes Metab. Syndr. Obes. 2014, 7, 587–591. [CrossRef]

37. El-Serag, H.B.; Graham, D.Y.; Satia, J.A.; Rabeneck, L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am. J. Gastroenterol. 2005, 100, 1243–1250. [CrossRef]

38. Lambert, D.M.; Marceau, S.; Forse, R.A. Intra-abdominal pressure in the morbidly obese. Obes. Surg. 2005, 15, 1225–1232. [CrossRef]

39. Bellville, J.W.; Bross, I.; Howland, W.S. Postoperative nausea and vomiting. IV. Factors related to postoperative nausea and vomiting. Anesthesiology 1960, 21, 186–193. [CrossRef]

40. McKie, B. Postoperative nausea and vomiting: A review of their incidence, causes and effects. Aust. N. Z. J. Surg. 1970, 39, 311–314. [CrossRef]

41. Palazzo, M.; Strunin, L. Anaesthesia and emesis. I: Etiology. Can. Anaesth. Soc. J. 1984, 31, 178–187. [CrossRef]

42. Lerman, J. Surgical and patient factors involved in postoperative nausea and vomiting. Br. J. Anaesth. 1992, 69, 24S. [CrossRef]

43. Muir, J.J.; Warner, M.A.; Oford, K.P.; Buck, C.F.; Harper, J.V.; Kunkel, S.E. Role of nitrous oxide and other factors in postoperative nausea and vomiting: A randomized and blinded prospective study. Anesthesiology 1987, 66, 513–518. [CrossRef] [PubMed]
42. Butterworth, J.F.; Mackey, D.C.; Wasnick, J.D. Morgan and Mikhail’s Clinical Anesthesiology; McGraw-Hill Education: New York, NY, USA, 2018.

43. Lemmens, H.J.M.; Saidman, L.J.; Eger, E.I.; Laster, M.J. Obesity Modestly Affects Inhaled Anesthetic Kinetics in Humans. Anesth. Analg. 2008, 107, 1864–1870. [CrossRef] [PubMed]

44. Collis, T.; Devereux, R.B.; Roman, M.J.; de Simone, G.; Yeh, J.-L.; Howard, B.V.; Fabsz, R.R.; Welty, T.K. Relations of stroke volume and cardiac output to body composition: The strong heart study. Circulation 2001, 103, 820–825. [CrossRef] [PubMed]

45. Gallagher, D.; Belmonte, D.; Deurenberg, P.; Wang, Z.; Krasnow, N.; Pi-Sunyer, F.X.; Heymsfield, S.B. Clinical pharmacokinetics of drugs in obesity. Clin. Pharmacokinet. 1993, 25, 103–114. [CrossRef] [PubMed]

46. Hanley, M.J.; Abernethy, D.R.; Greenblatt, D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 2010, 49, 71–87. [CrossRef] [PubMed]

47. Miller, R.D.; Eriksson, L.I.; Fleisher, L.A.; Wiener-Kronish, J.P.; Cohen, N.H.; Young, W.L. Miller’s Anesthesia E-Book; Philadelphia Elsevier Health Sciences: Amsterdam, The Netherlands, 2014.

48. Jain, R.; Chung, S.; Jain, L.; Khurana, M.; Lau, S.; Lee, J.; Vaidyanathan, J.; Zadezenskiy, I.; Choe, S.; Sahajwalla, C. Implications of obesity for drug therapy: Limitations and challenges. Clin. Pharmacol. Ther. 2011, 90, 77–89. [CrossRef]

49. Butterworth, J.F.; Mackey, D.C.; Wasnick, J.D. Morgan and Mikhail’s Clinical Anesthesiology; McGraw-Hill Education: New York, NY, USA, 2018.

50. Rodríguez-Morató, J.; Goday, A.; Langohr, K.; Pujadas, M.; Civit, E.; Pérez-Mañá, C.; Papaseit, E.; Ramon, J.M.; Benaiges, D.; Castañer, O., et al. Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity. Sci. Rep. 2019, 9, 20405. [CrossRef]

51. Jain, R.; Chung, S.; Jain, L.; Khurana, M.; Lau, S.; Lee, J.; Vaidyanathan, J.; Zadezenskiy, I.; Choe, S.; Sahajwalla, C. Implications of obesity for drug therapy: Limitations and challenges. Clin. Pharmacol. Ther. 2011, 90, 77–89. [CrossRef]

52. Abernethy, D.R.; Greenblatt, D.J. Drug disposition in obese humans. Clin. Pharmacokinet. 1986, 11, 199–213. [CrossRef]

53. Adams, J.; Murphy, P. Obesity in anaesthesia and intensive care. Br. J. Anaesth. 2000, 85, 91–108. [CrossRef]

54. Cheymol, G. Clinical pharmacokinetics of drugs in obesity. Clin. Pharmacokinet. 1993, 25, 103–114. [CrossRef] [PubMed]

55. Cheymol, G. Effects of obesity on pharmacokinetics. Clin. Pharmacokinet. 2000, 39, 215–231. [CrossRef] [PubMed]

56. Kim, E.-G.; Park, H.J.; Kang, H.; Choi, J.; Lee, H.J. Antiemetic effect of propofol administered at the end of surgery in laparoscopic assisted vaginal hysterectomy. Korean J. Anesthesiol. 2014, 66, 210–215. [CrossRef] [PubMed]

57. Gopalakrishnan, S.; Ganeshkumar, P. Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare. J. Family Med. Prim. Care 2013, 2, 9–14. [CrossRef] [PubMed]

58. Shaikh, S.I.; Nagarekha, D.; Hegade, G.; Marutheesh, M. Postoperative nausea and vomiting: A simple yet complex problem. Anesth. Essays Res. 2016, 10, 388–396. [CrossRef]

59. Jorgensen, E.A.; Knigge, U.; Warberg, J.; Kjaer, A. Histamine and the regulation of body weight. Neuroendocrinology 2007, 86, 210–214. [CrossRef] [PubMed]

60. Boden, G.; Chen, X.; Mozzoli, M.; Ryan, I. Effect of fasting on serum leptin in normal human subjects. J. Clin. Endocrinol. Metab. 1996, 81, 3419–3423. [CrossRef]

61. Moon, Y.E. Postoperative nausea and vomiting. Korean J. Anesthesiol. 2014, 67, 164–170. [CrossRef]

62. Abercrombie, E.D.; Keefe, K.A.; DiFrischia, D.S.; Zigmond, M.J. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J. Neurochem. 1989, 52, 1655–1658. [CrossRef]

63. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; Telang, F. Overlapping neuronal circuits in addiction and obesity: Evidence of systems pathology. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2008, 363, 3191–3200. [CrossRef] [PubMed]

64. Feinleib, J.; Kwan, L.H.; Yamani, A.; Davidson, A. Postoperative Nausea and Vomiting. UpToDate. 2018. Available online: https://www.uptodate.com/contents/postoperative-nausea-and-vomiting (accessed on 26 March 2020).
65. Kranke, P.; Eberhart, L.H.; Toker, H.; Roewer, N.; Wulf, H.; Kiefer, P. A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children. *Anesth. Analg.* 2007, 105, 1592–1597. [CrossRef] [PubMed]

66. Tramer, M.; Moore, A.; McQuay, H. Prevention of vomiting after paediatric strabismus surgery: A systematic review using the numbers-needed-to-treat method. *Br. J. Anaesth.* 1995, 75, 556–561. [CrossRef] [PubMed]

67. Ferrari, L.R.; Donlon, J.V. Metoclopramide reduces the incidence of vomiting after tonsillectomy in children. *Anesth. Analg.* 1992, 75, 351–354. [CrossRef]

68. Villeret, I.; Laffon, M.; Duchalais, A.; Blond, M.H.; Lecuyer, A.I.; Mercier, C. Incidence of postoperative nausea and vomiting in paediatric ambulatory surgery. *Paediatr. Anaesth.* 2002, 12, 712–717. [CrossRef]

69. Pocock, S.J.; Elbourne, D.R. Randomized trials or observational tribulations? *N. Engl. J. Med.* 2000, 342, 1907–1909. [CrossRef]

70. Concato, J.; Shah, N.; Horwitz, R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N. Engl. J. Med.* 2000, 342, 1887–1892. [CrossRef]

71. Benson, K.; Hartz, A.J. A comparison of observational studies and randomized, controlled trials. *N. Engl. J. Med.* 2000, 342, 1878–1886. [CrossRef]

72. Gum, P.A.; Thamilarasan, M.; Watanabe, J.; Blackstone, E.H.; Lauer, M.S. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. *JAMA* 2001, 286, 1187–1194. [CrossRef]

73. Hainer, V.; Aldhoon-Hainerová, I. Obesity paradox does exist. *Diabetes Care* 2013, 36, S276–S281. [CrossRef]

74. Nuttall, F.Q. Body Mass Index: Obesity, BMI, and Health: A Critical Review. *Nutr. Today* 2015, 50, 117–128. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).